Bevacizumab: A review of its use in metastatic colorectal cancer

Drugs

Volumn 68, Issue 4, 2008, Pages 487-506

  McCormack, Paul L ^a,b   Keam, Susan J ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis Drug Evaluations; Bevacizumab, general; Colorectal cancer

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PLACEBO; PLATINUM; RADIOSENSITIZING AGENT; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ABDOMINAL INFECTION; ABDOMINAL PAIN; ADJUVANT THERAPY; ANGIOGENESIS; AREA UNDER THE CURVE; ARTERY EMBOLISM; ARTERY THROMBOSIS; BLEEDING; BLOOD VESSEL PERMEABILITY; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG APPROVAL; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOTHELIUM CELL; EPISTAXIS; FEVER; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEALTH SERVICE; HUMAN; HYPERTENSION; LEUKOPENIA; LIVER METASTASIS; LOADING DRUG DOSE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NONHUMAN; PERFUSION; POSTOPERATIVE HEMORRHAGE; PROTEIN BLOOD LEVEL; PROTEINURIA; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RASH; RECTUM CARCINOMA; REVIEW; SCORING SYSTEM; SINGLE DRUG DOSE; STOMATITIS; THROMBOSIS; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; VASCULAR ENDOTHELIUM; VOMITING; WOUND COMPLICATION; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM METASTASIS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 40349100704     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868040-00009     Document Type: Review

References (64)

1. International Agency for Research on Cancer. GLOBOCAN 2002 database [online]. Available from URL: http://www-dep.iarc.fr [Accessed 2007 Dec 12]
2. Hoff PM. Bevacizumab in older patients and patients with poorer performance status. Semin Oncol 2006 Oct; 33 (5 Suppl. 10): S19-25
3. Natarajan N, Shuster TD. New agents, combinations, and opportunities in the treatment of advanced and early-stage colon cancer. Surg Clin North Am 2006 Aug; 86 (4): 1023-43
4. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992 Jun; 10 (6): 896-903
5. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000 Sep 28; 343 (13): 905-14
6. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000 Aug; 18 (16): 2938-47
7. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004 Jan 15; 22 (2): 229-37
8. Board RE, Valle JW. Metastatic colorectal cancer: current systemic treatment options. Drugs 2007; 67 (13): 1851-67
9. Diaz-Rubio E. Vascular endothelial growth factor inhibitors in colon cancer. Adv Exp Med Biol 2006; 587: 251-75
10. Genentech Inc. Avastin® (bevacizumab) for intravenous use: US prescribing information [online]. Available from URL: http://www.gene.com/gene/ products/information/oncology/avastin/insert.jsp [Accessed 2007 Dec 3]
11. European Medicines Agency. Avastin (bevacizumab) 25 mg/mL: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/avastin/H-582-PI-en.pdf [Accessed 2007 Jan 23]
12. Lyseng-Williamson KA, Robinson DM. Bevacizumab: a review of its use in advanced colorectal cancer, breast cancer, and NSCLC. Am J Cancer 2006; 5 (1): 43-60
13. Scott LJ. Bevacizumab: in first-line treatment of metastatic breast cancer. Drugs 2007; 67 (12): 1793-9
14. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997 Oct 15; 57 (20): 4593-9
15. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004 Aug; 25 (4): 581-611
16. André T, Kotelevets L, Vaillant JC, et al. VEGF, VEGF-B, VEGF-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int J Cancer 2000 Apr 15; 86 (2): 174-81
17. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993 Apr 29; 362: 841-4
18. Warren RS, Yuan H, Matli MR, et al. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995 Apr; 95: 1789-97
19. Yuan F, Chien Y, Dellian M, et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 1996 Dec; 93: 14765-70
20. Wildiers H, Guetens G, De Boeck G, et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003; 88: 1979-86
21. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004 Feb; 10 (2): 145-7
22. Koukourakis MI, Mavanis I, Kouklakis G, et al. Early antivascular effects of bevacizumab anti-VEGF monoclonal antibody on colorectal carcinomas assessed with functional CT imaging. Am J Clin Oncol 2007 Jun; 30 (3): 315-8
23. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 Jun 3; 350 (23): 2335-42
24. Jubb AM, Hurwitz HI, Bai W, et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006 Jan 10; 24 (2): 217-27
25. Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001 Feb 1; 19 (3): 851-6
26. Herbst RS, Johnson DH, Mininberg E, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005 Apr 10; 23 (11): 2544-55
27. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001 Feb 1; 19 (3): 843-50
28. Gaudreault J, Lieberman G, Kabbinavar F, et al. Pharmacokinetics (PK) of bevacizumab (BV) in colorectal cancer (CRC) [abstract no. PI-98]. Clin Pharmacol Ther 2001 Feb; 69 (2): P25
29. Brennan B, Siu L, Dhesy-Thind B, et al. Pharmacokinetic interactions between capecitabine, oxaliplatin and bevacizumab when used in combination for first-line treatment of metastatic colorectal cancer [abstract no. 2554]. J Clin Oncol 2007 Jun 20; 25 (18 Suppl.): 110s. Plus poster presented at the 43rd Annual Meeting of the American Society of Clinical Oncology; 2007 Jun 1-5; Chicago (IL)
30. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003 Jan 1; 21 (1): 60-5
31. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005 Jun 1; 23 (16): 3697-705
32. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007 Apr 20; 25 (12): 1539-44
33. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer [abstract no. 238, plus oral presentation]. 2007 Gastrointestinal Cancers Symposium; 2007 Jan 19-21; Orlando (FL)
34. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: final analysis of the TREE-study [abstract no. 3510]. J Clin Oncol 2006 Jun 20; 24 (18 Suppl.): 148s. Plus oral presentation presented at the 42nd Annual Meeting of the American Society of Clinical Oncology; 2006 Jun 2-6; Atlanta (GA)
35. Tournigand C, Lledo G, Delord J, et al. Modified FOLFOX7/bevacizumab or modified XELOX/bevacizumab with or without erlotinib in first-line metastatic colorectal cancer: results of the feasibility phase of the DREAM-OPTIMOX3 study (GERCOR) [abstract no. 4097]. J Clin Oncol 2007 Jun 20; 25 (18 Suppl.): 187s
36. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimsidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007 Oct 20; 25 (30): 4779-86
37. Saltz LB, Lenz H-J, Kindler HL, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007 Oct 10; 25 (29): 4557-61
38. Hecht JR. Updates in the management of gastrointestinal cancers: a report from the 9th World Congress on Gastrointestinal Cancer (WCGIC) [online]. Available from URL: http://www.ufscc.ufl.edu/Professional/content.aspx?section= conferencecoverage&id=40270 [Accessed 2007 Nov 12]
39. Kozloff M, Hainsworth J, Badarinath S, et al. Efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE) [abstract no. 3537]. J Clin Oncol 2006 Jun 20; 24 (18 Suppl.): 155s
40. Berry S, Cunningham D, Michael M, et al. Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI and fluoropyrimidines for mCRC: First BEAT trial. First BEAT Investigators [abstract no. 3020]. EJC Supplements 2007 Sep; 5 (4): 241. Plus poster presented at the 14th European Cancer Conference; 2007 Sep 23-27; Barcelona
41. Saltz L, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/N016966, a randomized phase III trial in first-line metastatic colorectal cancer [abstract no. 4028]. J Clin Oncol 2007 Jun 20; 25 (18 Suppl.): 170s. Plus abstract presented at the 43rd Annual Meeting of the American Society of Clinical Oncology; 2007 Jun 1-5; Chicago (IL)
42. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005 May 20; 23 (15): 3502-8
43. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004 Jan 1; 22 (1): 23-30
44. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005 Aug 1; 23 (22): 4866-75
45. Tyagi P, Grothey A. Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial. Clin Colorectal Cancer 2006 Nov; 6 (4): 261-4
46. Cassidy J, Clarke S, Diaz-Rubio E, et al. XELOX compared to FOLFOX4: survival and response results from XELOX-1/N016966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer [abstract no. 4030]. J Clin Oncol 2007 Jun 20; 25 (18 Suppl.): 171s. Plus poster presented at the 43rd Annual Meeting of the American Society of Clinical Oncology; 2007 Jun 1-5; Chicago (IL)
47. Amgen. Amgen discontinues Vectibix(TM) treatment in PACCE trial evaluating Vectibix(TM) as part of triple combination regimen: preliminary pre-planned interim analysis shows negative effect on progression-free survival [media release]. 2007 Mar 22
48. Golfinopoulos V, Salanti G, Pavlidis N, et al. Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol 2007 Oct; 8 (10): 898-911
49. Kozloff M, Hainsworth J, Badarinath S, et al. Survival of patients (pts) with mCRC treated with bevacizumab in combination with chemotherapy: results from the BRiTE registry [abstract no. 375 plus poster]. 4th Annual Gastrointestinal Cancers Symposium; 2007 Jan 19-21; Orlando (FL)
50. Grothey A, Sugrue M, Hedrick E, et al. Association between exposure to bevacizumab beyond first progression and overall survival in patients with metastatic colorectal cancer: results from a large observational study (BRiTE) [abstract no. 4036]. J Clin Oncol 2007 Jun 20; 25 (18 Suppl.): 172s. Plus poster presented at the 43rd Annual Meeting of the American Society of Clinical Oncology; 2007 Jun 1-5; Chicago (IL)
51. Hedrick E, Kozloff M, Hainsworth J, et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE) [abstract no. 3536]. J Clin Oncol 2006 Jun 20; 24 (18 Suppl.): 155s
52. Tappenden P, Jones R, Paisley S, et al. The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales. Eur J Cancer 2007 Nov; 43 (17): 2487-94
53. National Institute for Health and Clinical Excellence. Beva-cizumab and cetuximab for the treatment of metastatic colorectal cancer [online]. Available from URL: http://www.nice.org.uk/guidance/TA118/niceguidance/pdf/english [Accessed 2007 Oct 23]
54. Roche. Avastin receives broad label extension in Europe for the treatment of patients with metastatic colorectal cancer [media release]. 2008 Jan 28
55. de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997 Feb; 15 (2): 808-15
56. Van Cutsem EJD. Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. ESMO Guidelines Working Group. Ann Oncol 2007 Apr; 18 Suppl. 2: ii25-6
57. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colon cancer. Version 1.2008 [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf [Accessed 2007 Dec 17]
58. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: rectal cancer. Version 1.2008 [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/rectal.pdf [Accessed 2007 Dec 17]
59. O'Dwyer PJ. The present and future of angiogenesis-directed treatments of colorectal cancer. Oncologist 2006 Oct; 11 (9): 992-8
60. Giantonio BJ. Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings. Semin Oncol 2006 Oct; 33 (5 Suppl. 10): S15-8
61. Samalin E, Lièvre A, Boyer-Gestin C, et al. Efficacy of bevacizumab in combination with irinotecan or oxaliplatin as 2nd and 3rd or later-line treatment in metastatic colorectal cancer patients [abstract no. PD-0022]. Ann Oncol 2007 Jun 1; 18 Suppl. 7: 30. Plus poster presented at the 9th World Congress on Gastrointestinal Cancer; 2007 Jun 27-30; Barcelona
62. Figueras J, Lopez-Ben S, Albiol M, et al. Salvage surgery after neoadjuvant chemotherapy with bevacizumab in unselected patients with advanced CRC and unresectable systemic metastasis: resectability rate and post-operative outcome [abstract no. P-0012]. Ann Oncol 2007 Jun 1; 18 Suppl. 7: 34
63. Gruenberger B, Scheithauer W, Tamandl D, et al. Effectiveness of neoadjuvant chemotherapy including bevacizumab in patients with resectable colorectal cancer liver metastases [abstract no. 4060]. J Clin Oncol 2007 Jun 20; 25 (18 Suppl.): 178s. Plus poster presented at the 43rd Annual Meeting of the American Society of Clinical Oncology; 2007 Jun 1-5; Chicago (IL)
64. Reddy SK, Morse MA, Hurwitz HI, et al. Prolonged salvage treatment with bevacizumab for relapse after resection of colorectal liver metastases [abstract no. 182]. 4th Annual Gastrointestinal Cancers Symposium; 2007 Jan 19-21; Orlando (FL)